144 related articles for article (PubMed ID: 25179826)
1. Clinical outcome in patients with chronic antibody-mediated rejection treated with and without rituximab and intravenous immunoglobulin combination therapy.
Chung BH; Kim Y; Jeong HS; Hong YA; Choi BS; Park CW; Choi YJ; Kim YS; Yang CW
Transpl Immunol; 2014 Sep; 31(3):140-4. PubMed ID: 25179826
[TBL] [Abstract][Full Text] [Related]
2. Clinical Outcome of Rituximab and Intravenous Immunoglobulin Combination Therapy in Kidney Transplant Recipients with Chronic Active Antibody-Mediated Rejection.
Ban TH; Yu JH; Chung BH; Choi BS; Park CW; Kim YS; Yang CW
Ann Transplant; 2017 Aug; 22():468-474. PubMed ID: 28775248
[TBL] [Abstract][Full Text] [Related]
3. The effect of combination therapy with rituximab and intravenous immunoglobulin on the progression of chronic antibody mediated rejection in renal transplant recipients.
An GH; Yun J; Hong YA; Khvan M; Chung BH; Choi BS; Park CW; Choi YJ; Kim YS; Yang CW
J Immunol Res; 2014; 2014():828732. PubMed ID: 24741626
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of rituximab and intravenous immunoglobulin therapy in renal transplant recipients with chronic active antibody-mediated rejection.
Hong YA; Kim HG; Choi SR; Sun IO; Park HS; Chung BH; Choi BS; Park CW; Kim YS; Yang CW
Transplant Proc; 2012 Jan; 44(1):182-4. PubMed ID: 22310610
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of combination therapy for chronic antibody-mediated rejection in renal transplantation.
Kim MG; Kim YJ; Kwon HY; Park HC; Koo TY; Jeong JC; Jeon HJ; Han M; Ahn C; Yang J
Nephrology (Carlton); 2013 Dec; 18(12):820-6. PubMed ID: 24033843
[TBL] [Abstract][Full Text] [Related]
6. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection.
Waiser J; Budde K; Schütz M; Liefeldt L; Rudolph B; Schönemann C; Neumayer HH; Lachmann N
Nephrol Dial Transplant; 2012 Mar; 27(3):1246-51. PubMed ID: 21852274
[TBL] [Abstract][Full Text] [Related]
7. Long-term graft survival in patients with chronic antibody-mediated rejection with persistent peritubular capillaritis treated with intravenous immunoglobulin and rituximab.
Mulley WR; Huang LL; Ramessur Chandran S; Longano A; Amos LAR; Polkinghorne KR; Nikolic-Paterson DJ; Kanellis J
Clin Transplant; 2017 Sep; 31(9):. PubMed ID: 28640458
[TBL] [Abstract][Full Text] [Related]
8. Influence of preoperative anti-HLA antibodies on short- and long-term graft survival in recipients with or without rituximab treatment.
Ishida H; Furusawa M; Shimizu T; Nozaki T; Tanabe K
Transpl Int; 2014 Apr; 27(4):371-82. PubMed ID: 24438437
[TBL] [Abstract][Full Text] [Related]
9. Intravenous immunoglobulins and rituximab therapy for severe transplant glomerulopathy in chronic antibody-mediated rejection: a pilot study.
Bachelet T; Nodimar C; Taupin JL; Lepreux S; Moreau K; Morel D; Guidicelli G; Couzi L; Merville P
Clin Transplant; 2015 May; 29(5):439-46. PubMed ID: 25739833
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients.
Billing H; Rieger S; Ovens J; Süsal C; Melk A; Waldherr R; Opelz G; Tönshoff B
Transplantation; 2008 Nov; 86(9):1214-21. PubMed ID: 19005402
[TBL] [Abstract][Full Text] [Related]
11. Histopathologic features of transplant glomerulopathy associated with response to therapy with intravenous immune globulin and rituximab.
Kahwaji J; Najjar R; Kancherla D; Villicana R; Peng A; Jordan S; Vo A; Haas M
Clin Transplant; 2014 May; 28(5):546-53. PubMed ID: 24579925
[TBL] [Abstract][Full Text] [Related]
12. Impact of rituximab therapy for treatment of acute humoral rejection.
Kaposztas Z; Podder H; Mauiyyedi S; Illoh O; Kerman R; Reyes M; Pollard V; Kahan BD
Clin Transplant; 2009; 23(1):63-73. PubMed ID: 19200217
[TBL] [Abstract][Full Text] [Related]
13. One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled Trial.
Sautenet B; Blancho G; Büchler M; Morelon E; Toupance O; Barrou B; Ducloux D; Chatelet V; Moulin B; Freguin C; Hazzan M; Lang P; Legendre C; Merville P; Mourad G; Mousson C; Pouteil-Noble C; Purgus R; Rerolle JP; Sayegh J; Westeel PF; Zaoui P; Boivin H; Le Gouge A; Lebranchu Y
Transplantation; 2016 Feb; 100(2):391-9. PubMed ID: 26555944
[TBL] [Abstract][Full Text] [Related]
14. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience.
Jin MK; Cho JH; Kwon O; Hong KD; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
Transplant Proc; 2012 Jan; 44(1):200-3. PubMed ID: 22310614
[TBL] [Abstract][Full Text] [Related]
15. Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial.
Moreso F; Crespo M; Ruiz JC; Torres A; Gutierrez-Dalmau A; Osuna A; Perelló M; Pascual J; Torres IB; Redondo-Pachón D; Rodrigo E; Lopez-Hoyos M; Seron D
Am J Transplant; 2018 Apr; 18(4):927-935. PubMed ID: 28949089
[TBL] [Abstract][Full Text] [Related]
16. Rituximab, plasma exchange and immunoglobulins: an ineffective treatment for chronic active antibody-mediated rejection.
Piñeiro GJ; De Sousa-Amorim E; Solé M; Ríos J; Lozano M; Cofán F; Ventura-Aguiar P; Cucchiari D; Revuelta I; Cid J; Palou E; Campistol JM; Oppenheimer F; Rovira J; Diekmann F
BMC Nephrol; 2018 Oct; 19(1):261. PubMed ID: 30309322
[TBL] [Abstract][Full Text] [Related]
17. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
Mai ML; Ahsan N; Wadei HM; Genco PV; Geiger XJ; Willingham DL; Taner CB; Hewitt WR; Grewal HP; Nguyen JH; Hughes CB; Gonwa TA
Transplantation; 2009 Jan; 87(2):227-32. PubMed ID: 19155977
[TBL] [Abstract][Full Text] [Related]
18. Management of Chronic Active Antibody-Mediated Rejection in Renal Transplant Recipients: Single-Center Experience.
Nair P; Gheith O; Al-Otaibi T; Mostafa M; Rida S; Sobhy I; Halim MA; Mahmoud T; Abdul-Hameed M; Maher A; Emam M
Exp Clin Transplant; 2019 Jan; 17(Suppl 1):113-119. PubMed ID: 30777534
[TBL] [Abstract][Full Text] [Related]
19. Partial therapeutic response to Rituximab for the treatment of chronic alloantibody mediated rejection of kidney allografts.
Smith RN; Malik F; Goes N; Farris AB; Zorn E; Saidman S; Tolkoff-Rubin N; Puri S; Wong W
Transpl Immunol; 2012 Oct; 27(2-3):107-13. PubMed ID: 22960786
[TBL] [Abstract][Full Text] [Related]
20. Rabbit anti-human thymocyte immunoglobulin for the rescue treatment of chronic antibody-mediated rejection after pediatric kidney transplantation.
Cihan Y; Kanzelmeyer N; Drube J; Kreuzer M; Lerch C; Hennies I; Froede K; Verboom M; Ahlenstiel-Grunow T; Pape L
Pediatr Nephrol; 2017 Nov; 32(11):2133-2142. PubMed ID: 28717935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
